We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
-7.37%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$198M
AUM Growth
-$230M
(-54%)
Cap. Flow
-$211M
Cap. Flow
% of AUM
-106.78%
Top 10 Holdings %
Top 10 Hldgs %
42%
Holding
45
New
2
Increased
13
Reduced
11
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$5.64M |
| 2 |
Insulet
PODD
|
+$4.48M |
| 3 |
HCA Healthcare
HCA
|
+$4.1M |
| 4 |
UnitedHealth
UNH
|
+$2.46M |
| 5 |
Avantor
AVTR
|
+$2.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$12M |
| 2 |
Becton Dickinson
BDX
|
+$7.92M |
| 3 |
Elevance Health
ELV
|
+$6.66M |
| 4 |
Abbott
ABT
|
+$6.54M |
| 5 |
Merck
MRK
|
+$5.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioMarin Pharmaceuticals
BMRN
$13.6B
| $4.42M | 2.24% |
50,000
| – | – |
|
27
Vertex Pharmaceuticals
VRTX
$133B
| $4.33M | 2.19% |
12,460
-1,540
| -11% | -$539K |
|
|
28
Avantor
AVTR
$9.42B
| $3.79M | 1.92% |
180,000
+105,000
| +140% | +$2.23M |
|
|
CTLT
29
DELISTED
CATALENT, INC.
CTLT
| $3.64M | 1.84% |
80,000
+10,000
| +14% | +$467K |
|
30
IQVIA
IQV
$39.8B
| $3.44M | 1.74% |
17,500
-10,000
| -36% | -$2.17M |
|
|
31
Insulet
PODD
$10.1B
| $3.19M | 1.61% |
+20,000
| New | +$4.48M |
|
32
Icon
ICLR
$12.9B
| $2.46M | 1.24% |
10,000
-10,000
| -50% | -$2.52M |
|
33
Stevanato
STVN
$5.8B
| $2.26M | 1.14% |
76,072
+6,072
| +9% | +$190K |
|
|
34
Abbott
ABT
$192B
| – | – |
-60,000
| Closed | -$6.54M |
|
35
Alnylam Pharmaceuticals
ALNY
$30B
| – | – |
-8,000
| Closed | -$1.52M |
|
36
argenx
ARGX
$54.8B
| – | – |
-3,000
| Closed | -$1.17M |
|
|
37
Becton Dickinson
BDX
$50B
| – | – |
-30,000
| Closed | -$7.92M |
|
38
Biogen
BIIB
$30.9B
| – | – |
-10,000
| Closed | -$2.85M |
|
39
Charles River Laboratories
CRL
$13.6B
| – | – |
-13,000
| Closed | -$2.73M |
|
40
Community Health Systems
CYH
$410M
| – | – |
-300,000
| Closed | -$1.32M |
|
|
41
Elevance Health
ELV
$86.6B
| – | – |
-15,000
| Closed | -$6.66M |
|
|
GRFS
42
Grifois
GRFS
$5.4B
| – | – |
-62,843
| Closed | -$576K |
|
|
43
Merck
MRK
$328B
| – | – |
-50,000
| Closed | -$5.77M |
|
44
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| – | – |
-400,000
| Closed | -$177M |
|
45
Sarepta Therapeutics
SRPT
$1.94B
| – | – |
-811
| Closed | -$93K |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q3 2023 Portfolio in Review
As of Q3 2023, Sivik Global Healthcare held 45 positions worth $198M, down 54% from $428M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Sivik Global Healthcare withdrew a net $211M in Q3 2023, closing 12 positions and reducing 11 holdings. Its most notable exit was Becton Dickinson, an estimated $7.92M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 54% a quarter earlier.
Against the trend, Sivik Global Healthcare opened a new position in DexCom worth $4.67M.
- Sivik Global Healthcare's largest Q3 2023 buy was DexCom: 50,000 shares worth $4.67M.
- Sivik Global Healthcare added most to HCA Healthcare in Q3 2023, an estimated $4.1M increase.
- Sivik Global Healthcare's biggest Q3 2023 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $12M.
- Sivik Global Healthcare fully exited Becton Dickinson in Q3 2023, selling an estimated $7.92M.
- Sivik Global Healthcare's ten largest holdings make up 42% of its $198M portfolio in Q3 2023.
- Sivik Global Healthcare opened 2 new positions and closed 12 in Q3 2023.
- Sivik Global Healthcare's portfolio value fell 54% quarter-over-quarter to $198M.
Based on Sivik Global Healthcare's 13F filing for Q3 2023, filed 7 Nov 2023.